Relpax (Eletriptan hydrobromide) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Relpax

Headache »

What is a headache?

A Headache is defined as a pain in the head or upper neck. It is one of the most common locations of pain in the body and has many causes.

How are headaches classified?

Headaches have numerous causes, and in 2007 the International Headache Society agreed upon an updated classification system for headache. Because so many people suffer from headaches and because treatment sometimes is difficult, it is hoped that the new classification system will allow health care practitioners come to a specific diagnosis as to the type of headache and to provide better and more effective treatment.

There are three major categories of headaches:

primary headaches,
secondary headaches, and
cranial neuralgias, facial pain, and other headaches

What are primary headaches?

Primary headaches include migraine, tension, and cluster headaches, ...

Read the Headache article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Relpax User Reviews >>

Relpax

View the Headaches and Migraines Slideshow Pictures

A Visual Guide to Migraine Headaches Slideshow Pictures

Headache and Migraine Triggers Slideshow Pictures

Take the Migraines Quiz

font size

OVERDOSE

No significant overdoses in premarketing clinical trials have been reported. Volunteers (N=21) have received single doses of 120 mg without significant adverse effects. Daily doses of 160 mg were commonly employed in Phase III trials. Based on the pharmacology of the 5-HT_1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.

The elimination half-life of eletriptan is about 4 hours (see CLINICAL PHARMACOLOGY) and therefore monitoring of patients after overdose with eletriptan should continue for at least 20 hours, or longer should symptoms or signs persist.

There is no specific antidote to eletriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.

It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentration of eletriptan.

CONTRAINDICATIONS

RELPAX Tablets should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms, or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease (see WARNINGS).

RELPAX Tablets should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks (see WARNINGS).

RELPAX Tablets should not be given to patients with peripheral vascular disease including (but not limited to) ischemic bowel disease (see WARNINGS).

Because RELPAX Tablets may increase blood pressure, it should not be given to patients with uncontrolled hypertension (see WARNINGS).

RELPAX Tablets should not be administered to patients with hemiplegic or basilar migraine.

RELPAX Tablets should not be used within 24 hours of treatment with another 5-HT₁ agonist, an ergotamine-containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide.

RELPAX Tablets should not be used in patients with known hypersensitivity to eletriptan or any of its inactive ingredients.

RELPAX Tablets should not be given to patients with severe hepatic impairment.

Last reviewed on RxList: 6/1/2011
This monograph has been modified to include the generic and brand name in many instances.